You are here

Announcing the first stem cell translational journal

The potential of stem cells therapies and regenerative medicine is both provocative and unique, offering the distinct possibility of eventually repairing or replacing tissues damaged from disease, including certain cancers. Under the leadership of the esteemed scientist-clinician Anthony Atala, MD as Editor, STEM CELLS Translational Medicine will speed expertly executed translations of emerging lab discoveries into noteworthy clinical trials.

“This exciting new journal will foster the proper growth and ethical development in this fast-moving field. There is a gap in the existing stem cells journal spectrum that STEM CELLS Translational Medicine will fill,” said Dr. Atala. “SCTM is the sister journal to STEM CELLS, the thirty-year-old premier journal in the field, and together they will elevate our science to applications that will impact the lives of many patients.”

The California Institute for Regenerative Medicine (CIRM) has provided a 3-year seed grant in support of the publication of SCTM.

“Science moves forward through publications in outstanding, peer-reviewed journals,” said Dr. Alan Trounson, CIRM President. “This new journal will provide a venue for studies that move stem cell research closer toward clinical trials. In addition to publishing new discoveries that help all scientists in their goals the journal will also take the unusual step of publishing studies considered “negative,” with results that did not back up the original hypothesis or that did not show a new path to therapies, which will save other scientists the time of carrying out those experiments.”

In addition, the journal will launch a multi-media platform, allowing for the production of series of online podcasts that focus on methods or clinical processes and feature key opinion leaders and thought-provoking roundtables to highlight important issues or feature premier stem cells institutes and laboratories.

SCTM will be available in December 2011.



About AlphaMed Press - Established in 1983, AlphaMed Press with offices in Durham, NC, Sausalito, CA, and Belfast, Northern Ireland, publishes three internationally renowned peer-reviewed journals with globally recognized editorial boards dedicated to advancing knowledge and education in their focused disciplines: STEM CELLS®, now in its 29th year, is the world's first journal devoted to this fast paced field of research. The Oncologist®, also a monthly peer-reviewed publication, is in its 16th year and is devoted to community and hospital-based oncologists and physicians entrusted with cancer patient care. STEM CELLS Translational Medicine will be available by December 2011. AlphaMed Press publishes the Stem Cells Portal ( and The Oncologist Community ( online, as well as freestanding monographs and books, and is renowned for its excellence and speed in the publication of the peer-reviewed proceedings of major international symposia.